These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 4200307

  • 1. Clinical pharmacology of dibromohexitols.
    Eckhardt S.
    Haematologica; 1972 Apr; 57(11):722-31. PubMed ID: 4200307
    [No Abstract] [Full Text] [Related]

  • 2. [Clinical experiences with Dibromdulcitol (DBD) in the treatment of cancer].
    Nyiredy G, Gévai E.
    Bronches; 1971 Apr; 21(2):202-6. PubMed ID: 5126170
    [No Abstract] [Full Text] [Related]

  • 3. The effect of dibromodulcitol (NSC 104800) on intravenously induced cytemia of rats.
    Németh L.
    Neoplasma; 1971 Apr; 18(5):533-7. PubMed ID: 5119525
    [No Abstract] [Full Text] [Related]

  • 4. Potential antitumor agents. Some 1,6-disubstituted galactitol and mannitol derivatives.
    Acton EM, Keyanpour-Rad M, Christensen JE, Tong HH, Kwok RP, Goodman L.
    Carbohydr Res; 1972 May; 22(2):477-86. PubMed ID: 5047748
    [No Abstract] [Full Text] [Related]

  • 5. Initial clinical trial of dibromodulcitol (NSC-104800) in patients with advanced cancer.
    Keyes JW, Selawry OS, Hansen HH.
    Cancer Chemother Rep; 1971 Dec; 55(5):583-9. PubMed ID: 5003621
    [No Abstract] [Full Text] [Related]

  • 6. Current concepts in the treatment of chronic myelocytic leukemia.
    Sokal JE.
    Annu Rev Med; 1973 Dec; 24():281-8. PubMed ID: 4575858
    [No Abstract] [Full Text] [Related]

  • 7. Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.
    Ahmann DL, Bisel HF, Edmonson JH, Hahn RG, O'Connell MJ, Frytak S.
    Cancer Treat Rep; 1976 Nov; 60(11):1681-2. PubMed ID: 1021239
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC-132313).
    Németh L, Institóris L, Somfai S, Gál F, Pályi I, Sugár J, Csuka O, Szentirmay Z, Kellner B.
    Cancer Chemother Rep; 1972 Oct; 56(5):593-602. PubMed ID: 4652589
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 1,2:5,6-Dianhydrogalactitol in advanced breast cancer.
    Hoogstraten B, O'Bryan R, Jones S.
    Cancer Treat Rep; 1978 May; 62(5):841-2. PubMed ID: 657167
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A comparative essay of drugs in the treatment of chronic myeloid leukaemia.
    Petrany G.
    Haematologica; 1972 Apr; 57(11):717-21. PubMed ID: 4200306
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. New trends in the management of chronic myeloid leukaemia.
    Tura S.
    Haematologica; 1972 Apr; 57(11):741-52. PubMed ID: 4200309
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.